From May 23 to 25, the "2025 Nanshan Respiratory Health Forum and the Four-Year Anniversary Series of Academic Events Celebrating the Establishment of Guangzhou National Laboratory" was successfully held in Guangzhou. As a premier academic platform for respiratory health, the forum brought together world-class experts, leading research institutions, and industry representatives to jointly discuss the latest advancements and future trends in the diagnosis and treatment of respiratory diseases. Jiuzhitang Maker stood out at the event with its clinical trial project—collaborating with the First Affiliated Hospital of Guangzhou Medical University—to explore stem-cell therapy for a rare lung condition called alveolar proteinosis (aPAP), unveiling interim study results that offer new hope for treating this uncommon disease.

The trial is steadily advancing, and initial positive signals are emerging.

At this forum, Jiuzhitang Maker unveiled the interim research findings from its clinical trial project on stem cell therapy for pulmonary alveolar proteinosis, conducted in collaboration with the First Affiliated Hospital of Guangzhou Medical University. Currently, the study is advancing into a critical phase and has already demonstrated promising initial results. Through meticulous patient monitoring and comprehensive data collection, the research team observed notable signs of improvement in some participants—specifically, partial recovery of physical function—which not only highlight the potential benefits of stem cell treatment but also provide valuable insights and guidance for future research efforts. While the full therapeutic efficacy still requires further validation, these early-stage findings undeniably serve as a powerful catalyst to keep the project moving forward.

Deeply integrating industry, academia, and research to jointly build a leading hub for innovative studies

Jiuzhitang Maker's collaboration with the First Affiliated Hospital of Guangzhou Medical University stands as a prime example of deep integration between industry, academia, and research. Leveraging its extensive expertise in respiratory disease diagnosis and treatment, the First Affiliated Hospital of Guangzhou Medical University has provided precise patient selection, standardized clinical protocols, and rigorous quality control for the trial. Meanwhile, Jiuzhitang Maker, backed by its cutting-edge technologies and innovative capabilities in stem-cell-based pharmaceuticals, has contributed an advanced R&D platform and invaluable technical support to the project. Together, the two partners have worked closely, maximizing their respective strengths to accelerate the clinical trial process and significantly enhance the efficiency of translating research findings into practical applications.

Active forum discussions spark vibrant exchanges of ideas.

Jiuzhitang Maker set up a dedicated booth at the forum, becoming a popular hub for attendees to connect and engage in lively discussions. Through a variety of engaging formats—such as multimedia presentations, physical models, and expert-led explanations—the company comprehensively showcased its R&D journey, core technologies, and key milestones in the field of stem-cell-based pharmaceuticals. Renowned domestic and international experts, scholars, and industry leaders eagerly stopped by the booth to delve into in-depth conversations with Jiuzhitang Maker’s researchers. Topics of discussion included the mechanisms of stem cells, the significance of the company’s recent breakthroughs, the challenges encountered during the research process, and promising directions for future development. Experts highly praised Jiuzhitang Maker’s innovative technologies and impressive progress in its ongoing research, while also offering valuable, constructive feedback to further enhance the company’s initiatives.

The road ahead is long and arduous, but Jiuzhitang Maker fully understands that stem-cell drug development still faces numerous challenges. Yet, the company will seize this forum as an opportunity to remain steadfast in its confidence, ramp up R&D investments, continuously integrate resources, strengthen collaborations, and vigorously accelerate the translation of stem-cell research breakthroughs into clinical applications. In doing so, we aim to bring more treatment options and hope to patients suffering from pulmonary alveolar proteinosis—and ultimately contribute even more significantly to the growth of the stem-cell pharmaceutical industry.